1 Royalty Pharma Plc Receivables Turnover Ratio (RPRX), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Royalty Pharma Plc  (NASDAQ: RPRX)
 

Royalty Pharma Plc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Royalty Pharma Plc's ability to collect accounts receivable sequentially worsen to 0.59, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Royalty Pharma Plc's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 619 days, from 598 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 460 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3129, from overall ranking in the first quarter 2026 at 3363.

What is Receivable Turnover Ratio?
What is Royalty Pharma Plc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RPRX Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change 6.92 % - - - -
Y / Y Revenue Change 16.5 % 10.97 % 4.78 % 7.9 % 7.71 %
Receivable Turnover Ratio (TTM) 0.59 0.61 0.6 0.59 0.58
RPRX's Total Ranking # 3129 # 3363 # 2749 # 3005 #
Accounts Receivable average collection period days 615 597 613 620 632
Seq. Receivable Change - - - - -
Seq. Revenue Change 6.91 % 1.38 % 2.08 % 5.29 % 1.83 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 152
Healthcare Sector # 461
Overall Market # 3129

Receivable Turnover Ratio Statistics
High Average Low
0.18 0.08 0
(Dec 31 2020)   (Jun 30 2013)





RPRX Company Profile • Back to RPRX Efficiency Comparisons • Compare RPRX Receivables Turnover Ratio to its Competitors

Financial Statements
Royalty Pharma Plc's Accounts Receivable $ 17,082 Millions Visit RPRX's Balance sheet
Royalty Pharma Plc's Sales TTM $ 2,536 Millions Visit RPRX's Income Statement
Sources of RPRX's Revenues Visit RPRX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RPRX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RPRX's Growth Rates RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Dividend Comparisons
RPRX's Profitability Ratios RPRX's Roi RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Valuation Ratios RPRX's Roe RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.